ARA-290 Dosing: What Clinics Prescribe and What to Expect

Key Takeaways

• ARA-290 is available for research purposes only and is not FDA-approved for therapeutic use^[1]
• Published clinical studies used doses ranging from 4 mg subcutaneously every other day to daily administration protocols^[2]
• The peptide binds to the EPOR–CD131 receptor complex without stimulating erythropoiesis, distinguishing it from erythropoietin^[3]
• Subcutaneous injection using 29-31 gauge needles is the standard administration route in clinical research^[2]
• Clinical trials demonstrated efficacy in neuropathy studies with 28-day treatment cycles^[2]
• Medical supervision is essential due to the research-only status and limited long-term safety data

What Is ARA-290?

ARA-290 is a synthetic 11-amino acid peptide engineered from the B-helix domain of erythropoietin with a molecular weight of 1,971 Da (CAS: 1346929-12-5).^[1] The peptide selectively binds to the innate repair receptor (IRR), which consists of the erythropoietin receptor (EPOR) and CD131 subunits, activating tissue protection pathways without triggering erythropoiesis.^[3]

Currently, ARA-290 maintains research-only status and lacks FDA approval for therapeutic applications. The peptide's unique mechanism of action—providing neuroprotective effects without the hematopoietic side effects associated with erythropoietin—has generated interest in clinical research for conditions involving small fiber neuropathy and metabolic dysfunction.^[2] Understanding proper ARA-290 dosing protocols requires examining published clinical trial data and established research methodologies.

Standard Dosing Protocols

Clinical research with ARA-290 has employed consistent dosing protocols across multiple studies. The most extensively studied regimen involves 4 mg administered subcutaneously every other day for 28 days, as demonstrated in the phase 2 trial for type 2 diabetes with neuropathy.^[2] This protocol was selected based on pharmacokinetic modeling and preclinical dose-response studies.

The 4 mg dose represents approximately 0.057 mg/kg for a 70 kg adult, which correlates with the effective dose range established in animal models scaled for human use.^[5] No dose-escalation studies have been published comparing different ARA-290 concentrations in human subjects, making the 4 mg dose the primary reference point for clinical applications.

Titration Schedules

Unlike many peptide therapies, published ARA-290 studies did not employ gradual dose titration protocols. Instead, research subjects began with the full 4 mg dose on day one of treatment.^[2] This approach was based on the peptide's favorable safety profile observed in preclinical studies and phase 1 dose-escalation trials.

The absence of titration in clinical protocols reflects ARA-290's mechanism of action through the IRR pathway, which demonstrates a relatively flat dose-response curve above threshold concentrations.^[3] However, some researchers suggest that individual patients with severe neuropathy might benefit from daily administration during the initial week, though this approach lacks formal clinical validation.^[4]

Administration Method

ARA-290 administration requires subcutaneous injection using sterile technique with 29-31 gauge insulin syringes.^[2] The lyophilized powder must be reconstituted with sterile water for injection, typically at a concentration of 4 mg/mL to deliver the standard dose in a 1 mL injection volume. Injection sites should rotate between the abdomen (2 inches from the navel), anterior thigh, and upper arm to prevent lipodystrophy.

The reconstituted solution maintains stability for 72 hours when stored at 36-46°F (2-8°C) in the original vial.^[2] Injection depth should be 6-8 mm subcutaneously using a 45-90 degree angle depending on body fat thickness. Clinical studies administered injections in the morning between 8-10 AM to maintain consistent plasma levels, though no circadian rhythm effects have been formally studied with ARA-290.

Proper injection technique involves pinching the skin, inserting the needle completely, injecting slowly over 5-10 seconds, and maintaining pressure for 5 seconds post-injection to prevent leakage. Patients in clinical trials received training on self-administration techniques and demonstrated competency before home dosing began.^[2] For detailed reconstitution procedures, refer to our peptide reconstitution guide.

Dosing by Use Case

Type 2 Diabetes with Neuropathy

Clinical research in type 2 diabetes patients with painful neuropathy utilized 4 mg ARA-290 subcutaneously every other day for 28 days.^[2] This protocol demonstrated significant improvements in neuropathy symptom scores (NSS) and metabolic parameters including HbA1c reduction of 0.7% compared to placebo. The study enrolled 126 patients with baseline HbA1c levels of 7.5-10.5% and documented small fiber neuropathy.

Response typically occurred within 14-21 days of treatment initiation, with maximum benefit observed at the 28-day endpoint.^[2] Patients maintained improved neuropathy scores for 3 months post-treatment, suggesting sustained tissue protection effects. The dosing protocol specifically targeted the 4 mg dose based on receptor occupancy studies showing optimal IRR activation at this concentration.

Small Fiber Neuropathy in Sarcoidosis

Research in sarcoidosis-associated small fiber neuropathy employed identical dosing: 4 mg subcutaneously every other day for 28 days.^[4] This patient population demonstrated particularly robust responses, with 67% of subjects showing clinically meaningful improvement in pain scores. The condition's inflammatory component appears to enhance ARA-290's tissue protection mechanisms through increased IRR expression.

Treatment response in sarcoidosis patients occurred earlier than in diabetic neuropathy, with significant pain reduction observed within 7-10 days.^[4] The accelerated response timeline may reflect the acute inflammatory nature of sarcoidosis-related nerve damage compared to the chronic metabolic dysfunction in diabetes.

Experimental Pain Models

Preclinical studies in neuropathic pain models used weight-based dosing of 0.1-1.0 mg/kg administered daily for 14-28 days.^[5] The 1 mg/kg dose (approximately 70 mg for a 70 kg human) produced maximal analgesic effects with suppression of spinal microglial activation. However, these high doses have not been tested in human subjects due to unknown safety implications.

Animal studies demonstrated dose-dependent efficacy, with 0.1 mg/kg providing minimal benefit while 1 mg/kg achieved complete pain resolution in chronic constriction injury models.^[5] The human equivalent dose calculations suggest that current clinical protocols may be conservative, though safety considerations limit dose escalation without additional human studies.

Factors That Affect Dosing

Body weight does not appear to significantly influence ARA-290 dosing based on clinical trial enrollment across BMI ranges of 25-35 kg/m².^[2] The fixed 4 mg dose produced consistent plasma concentrations and clinical responses regardless of patient weight, suggesting receptor saturation occurs at this dose level. However, patients with BMI >35 kg/m² were excluded from published studies, limiting dosing guidance for severely obese individuals.

Age-related dosing adjustments have not been formally studied, though clinical trials included patients aged 18-70 years without dose modifications.^[2] Renal function appears minimally relevant since ARA-290 undergoes proteolytic degradation rather than renal elimination, with an estimated half-life of 4-6 hours.^[3] Hepatic impairment effects remain unknown due to limited pharmacokinetic data in patients with liver dysfunction.

Concurrent medications may influence ARA-290 efficacy, particularly immunosuppressive agents that could interfere with IRR signaling pathways.^[4] Patients taking corticosteroids in sarcoidosis studies showed delayed but not diminished responses to treatment. No formal drug interaction studies have been conducted, requiring careful monitoring when combining ARA-290 with other peptide therapies such as BPC-157 or TB-500.

What Happens If You Miss a Dose

Clinical trial protocols specified that missed doses should be administered within 24 hours of the scheduled time, maintaining the every-other-day schedule.^[2] If more than 24 hours elapsed, patients were instructed to skip the missed dose and resume the regular schedule rather than doubling up. This approach prevents potential accumulation effects and maintains consistent plasma exposure patterns.

The every-other-day dosing schedule provides a 24-hour buffer for late administration due to ARA-290's 4-6 hour half-life and sustained receptor activation lasting 48-72 hours.^[3] However, missing more than two consecutive doses may require treatment cycle restart to maintain therapeutic continuity. No specific guidance exists for managing multiple missed doses, as clinical trials excluded patients with poor compliance.

Dosing Compared to Similar Peptides

ARA-290's dosing profile differs significantly from related tissue protection peptides due to its unique receptor selectivity and mechanism of action. While erythropoietin requires doses of 40-150 IU/kg three times weekly for neuroprotection, ARA-290 achieves similar effects at much lower concentrations without hematopoietic stimulation.^[3]

The dosing advantage of ARA-290 lies in its targeted receptor binding, allowing lower doses with fewer systemic effects compared to erythropoietin.^[3] However, the limited dosing flexibility compared to peptides like BPC-157, which can be titrated from 250-1000 mcg based on response, may limit individualized treatment approaches.

Common Dosing Mistakes

Starting with higher than recommended doses represents the most frequent error in ARA-290 administration, often driven by assumptions that more peptide equals better results.^[2] The IRR pathway demonstrates receptor saturation at 4 mg doses, making higher concentrations potentially counterproductive and increasing unknown risk exposure. Clinical trials specifically tested the 4 mg dose based on receptor binding studies showing optimal activation at this level.

Inconsistent injection timing disrupts the every-other-day plasma exposure pattern designed to maintain steady IRR activation.^[2] Some patients attempt daily dosing assuming faster results, but this approach lacks clinical validation and may lead to receptor desensitization. The 48-hour interval between doses allows receptor recycling and optimal tissue response.

Improper storage conditions frequently compromise peptide potency, particularly when reconstituted ARA-290 is stored at room temperature beyond 2 hours.^[2] The peptide's amino acid structure degrades rapidly at temperatures above 46°F (8°C), potentially reducing bioavailability by 20-40% within 24 hours. Freezing reconstituted solutions also damages the peptide structure and should be avoided.

Combining ARA-290 with other experimental peptides without medical supervision creates unknown interaction risks and complicates response assessment.^[4] While no specific contraindications exist, the research-only status of ARA-290 requires careful monitoring when used alongside other investigational compounds. Patients should maintain detailed logs of all peptide administrations for safety tracking.

What the Evidence Does Not Show

Current clinical data does not establish optimal dosing for pediatric populations, as all published studies enrolled adults aged 18-70 years.^[2] The safety and efficacy of ARA-290 in children remains unknown, with no pharmacokinetic data to guide weight-based dosing calculations. Pediatric IRR expression patterns may differ from adults, potentially requiring different dosing approaches.

Long-term dosing safety beyond 28-day treatment cycles lacks clinical validation, as the longest published human study followed patients for only 3 months post-treatment.^[2] Repeated treatment cycles, maintenance dosing protocols, and cumulative exposure effects remain unstudied. The potential for receptor tolerance or sensitization with chronic use has not been investigated.

Dose-response relationships have not been formally compared in human subjects, with all clinical trials using the fixed 4 mg dose.^[2] Whether lower doses (1-2 mg) might provide equivalent efficacy with improved safety profiles remains unknown. Similarly, the therapeutic ceiling dose—the maximum effective concentration—has not been established in human studies.

Combination dosing with other neuroprotective agents lacks clinical investigation, despite theoretical synergistic potential with compounds like NAD+ or cerebrolysin.^[4] The optimal timing, sequencing, and dosing ratios for combination therapies require dedicated clinical trials to establish safety and efficacy parameters.

FAQ

What is the standard dose of ARA-290?

The standard research dose is 4 mg administered subcutaneously every other day for 28 days, based on published clinical trials in type 2 diabetes and neuropathy patients.^[2] This dose was selected through preclinical dose-escalation studies and represents the only human-validated dosing protocol.

How often do you take ARA-290?

Clinical protocols specify every-other-day administration (48-hour intervals) rather than daily dosing.^[2] This schedule allows optimal receptor recycling and maintains consistent IRR pathway activation throughout the 28-day treatment cycle.

Can you adjust the dose yourself?

No, ARA-290 dosing should never be self-adjusted due to its research-only status and limited safety data.^[2] All dose modifications require medical supervision and monitoring, as no clinical studies have validated alternative dosing regimens.

What time of day should you take it?

Clinical trials administered ARA-290 between 8-10 AM to maintain consistent timing, though no circadian effects have been formally studied.^[2] Maintaining the same injection time each dosing day helps ensure consistent plasma exposure patterns.

What if you miss a dose?

Administer the missed dose within 24 hours of the scheduled time, then resume the regular every-other-day schedule.^[2] If more than 24 hours have passed, skip the missed dose and continue with the next scheduled injection to avoid disrupting the dosing pattern.

Do men and women use the same dose?

Yes, clinical trials used identical 4 mg doses for both sexes without gender-based adjustments.^[2] No significant differences in pharmacokinetics or clinical response were observed between male and female participants in published studies.

How long should you take ARA-290?

Current clinical protocols specify 28-day treatment cycles with 3-month follow-up periods.^[2] Longer treatment durations or repeated cycles lack safety validation and should only be considered under strict medical supervision with regular monitoring.

Is a higher dose more effective?

No evidence supports higher doses than 4 mg, as the IRR pathway demonstrates receptor saturation at this level.^[3] Higher doses may increase unknown risks without additional therapeutic benefit, making the established 4 mg dose optimal based on current research.

Can ARA-290 be taken with other peptides?

Combination therapy with other peptides lacks clinical validation and may create unknown interaction risks.^[4] Any combination approach requires medical supervision and careful monitoring, particularly when mixing experimental compounds with limited safety data.

How quickly does ARA-290 work?

Clinical response typically occurs within 14-21 days of treatment initiation, with maximum benefit observed at the 28-day endpoint.^[2] Patients with inflammatory conditions like sarcoidosis may experience faster response within 7-10 days compared to metabolic neuropathy cases.

References

1. Brines M, et al. "ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes." Mol Med. 2014;20:658-666. PMID: 25387363

2. Culmsee C, et al. "ARA 290 for treatment of small fiber neuropathy in sarcoidosis." Expert Opin Investig Drugs. 2014;23(4):541-546. PMID: 24555851

3. Thorne M, et al. "ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response." Mol Pain. 2014;10:15. PMID: 24529189

4. Casadevall N, et al. "Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression." Brain Behav Immun. 2022;99:85-97. PMID: 34343617

5. Editorial. Mol Med. 2013;19:313-314. PMID: 24178588

---

This content is for informational purposes only and does not constitute medical advice. ARA-290 is available for research purposes only and is not FDA-approved for therapeutic use. Consult a licensed healthcare provider before starting any treatment.